$INVX

Reddout Mark sold $301K of INVX

Reddout Mark (President of North America) sold 10,750 shares of Innovex International, Inc. (INVX) at $28.00 ($0.30M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reddout Mark
Published Jun 3, 2026, 10:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 10:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$INVX
Neutral
medium confidence
Mentioned
$INVX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INVXNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but is not a fundamental catalyst; 10b5-1 plans generally weaken the predictive value of insider sales.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 designation suggests low incremental risk to the stock’s fundamentals.

03

What to watch

The filing does not indicate whether other insiders or institutions changed positions around the same time, limiting inference from this one transaction.

Relevance 6/10Novelty 3/10Timing: After-hours SEC Form 4 filed 2026-06-03 for a 2026-06-02 sale.

Background

This is an SEC Form 4 insider transaction disclosure (officer/direct holdings) for Innovex International, Inc.

Company-level read

Ticker impact

$INVXNeutralMedium confidence
Context

Innovex International officer Mark Reddout sold 10,750 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 context.

Evidence & confidence

The filing specifies an open-market sale and a pre-arranged Rule 10b5-1 plan, which typically reduces the signal strength versus discretionary selling.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Innovex International, Inc.

    Subject of the Form 4 insider sale by officer Mark Reddout.

  • Mark Reddout

    President of North America who sold 10,750 shares at $28.00/share under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INVXMedAI 8/10

Innovex (INVX) Q2 2026 Earnings Call Transcript

Innovex (INVX) reported Q2 2026 revenue of $245 million, up 2% sequentially and 9% year over year, with adjusted EBITDA of $48 million (20% margin) and free cash flow of $30 million. Management cited international/offshore growth and Mexico activity, plus a $95 million TCO Group acquisition completed July 1. Q3 guidance calls for $260 million to $270 million revenue and $51 million to $57 million adjusted EBITDA.

Med

Innovex International, Inc. Q2 2026 Earnings Call Summary

Innovex International, Inc. reported Q2 progress driven by higher international activity and subsea momentum, aided by integration of Dril-Quip and cross-selling. It acquired TCO Group, expecting Q3 2026 revenue of $15M and EBITDA of $3M from TCO. Middle East air freight added a $1.5M margin headwind. TCO was funded with $65M cash and $30M stock.

$INVXMed

Innovex International, Inc. (INVX): Results of Operations and Financial Condition

Innovex International, Inc. (INVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Innovex Announces Second Quarter 2026 Results HOUSTON, August 3, 2026 – Innovex International, Inc. (NYSE: INVX) (“Innovex,” the “Company” or “we”) today announced financial and operating results for the second quarter of 2026. Second Quarter Highlights • Revenue of $245 million,

$INVXMed

Innovex buys TCO Group in $95m deal

Innovex International completed its acquisition of TCO Group in a cash-and-stock deal valued at $95m, according to Innovex. The company says the purchase should be accretive to EPS, improve returns over time, and expand global sales of TCO’s glass barrier technologies via Innovex’s commercial platform, including Norway and the UAE.